Cristina Ghenoiu, PhD, is a Partner in Mubadala Capital’s venture business, focused on biotech investments, with a 15-year track record spanning public markets, crossovers, Series A/B financings, and company creation and operations; she joined Mubadala in September 2023 and soon after led its investment in Capstan Therapeutics, acquired by AbbVie for up to $2.1bn in July 2025. Previously, she was a Principal on RA Capital’s venture team (2021–2023) and a Vice President on Longitude Capital’s Biotech Team (2016–2020), where she helped spin out and raise an $85M Series A for Epirium Bio and later joined the company as Senior Vice President, R&D Oerations & New Product Planning (2019–2021). Across Longitude and RA, she played key roles in financing Vaxcyte (PCVX), CuraSen, Molecular Templates (MTEM), and venture builds including 89bio (ETNB, acquired by Roche for up to $3.5bn in September 2025), Capacity Bio, GIVAX, Rivus Pharma (scientific co-founder), and Superluminal Medicines. Earlier in her career, she was an associate analyst in biotechnology equity research at TD Cowen (2013–2016). Cristina completed postdoctoral training at The Rockefeller University with first-author publications in Science, Molecular Cell, and JCB, and holds a PhD in Chromosome and Cell Biology from Cornell University and a BA in Biochemistry from Mount Holyoke College (Magna cum laude), with High Honors for a Computational Quantum Chemistry thesis.
